There are currently 2866 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066
Recruiting
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.
Gender:
ALL
Ages:
Between 2 years and 30 years
Trial Updated:
01/21/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
Register for Updates
Anesthetics and Analgesics in Children
NCT03427736
Recruiting
The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
01/21/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Anesthesia, Pain
Register for Updates
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Houston Methodist, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
Intravesical BCG vs GEMDOCE in NMIBC
NCT05538663
Recruiting
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will result in a non-inferior event-free survival (EFS) compared to standard treatment with intravesical BCG. The purpose of this study is to test whether Gemcitabine + Docetaxel is a better or worse treatment than the usual BCG therapy approach. The primary objective of this study is to determine the event free survival (EFS) of BCG-naïve high gr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas +5 locations
Conditions: Non-muscle-invasive Bladder Cancer
Register for Updates
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
NCT04779320
Recruiting
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
01/17/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Crohn's Disease (CD)
Register for Updates
Study of RP-6306 Alone or in Combination with RP-3500 or Debio 0123 in Patients with Advanced Solid Tumors
NCT04855656
Recruiting
The primary purpose of this study is to assess the safety and tolerability of RP-6306 alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/17/2025
Locations: Participating Site # 1001, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
NCT06782555
Recruiting
The purpose of this Phase 1/2 study is to test the overall safety, tolerability, and effectiveness of the combination investigational drugs evofosfamide, zalifrelimab, and balstilimab in treating advanced or metastatic castration-resistant prostate cancer, pancreatic cancer, and human papilloma virus (HPV)-negative squamous cell carcinoma of the head and neck (SCCHN).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Register for Updates
Hypophysectomy by Stereotactic Radiosurgery for Cancer-Related Pain
NCT06287515
Recruiting
To learn if hypophysectomy (treatment of the pituitary gland) using a type of radiation treatment called stereotactic radiosurgery (SRS) can help to relieve cancer-related pain.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Hypophysectomy
Register for Updates
Effectiveness of CRD-4730 in Participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
NCT06005428
Recruiting
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
01/17/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: CPVT1, Heart Defects, Congenital, Heart Diseases, Ventricular Tachycardia
Register for Updates
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983
Recruiting
This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC infants. This study is supported by research funding from the Office of Orphan Products Division (OOPD) of the US Food and Drug Administration (FDA).
Gender:
ALL
Ages:
Between 1 day and 6 months
Trial Updated:
01/17/2025
Locations: University of Texas HSC at Houston, Houston, Texas
Conditions: Tuberous Sclerosis Complex, Epilepsy
Register for Updates
Survey of Human Rabies Immune Globulin Safety in Children
NCT05382650
Recruiting
This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
01/17/2025
Locations: Houston Methodist, Houston, Texas +1 locations
Conditions: Rabies, Rabies Human, Rabies Virus Infection, Pediatrics
Register for Updates
Cord Clamping Among Neonates with Congenital Heart Disease
NCT06153459
Recruiting
The goal of this clinical trial is to compare 2 different timepoints for clamping the umbilical cord at birth for term-born infants with a prenatal diagnosis of congenital heart disease (CHD). The main questions it aims to answer are: * Does Delayed Cord Clamping at 120 seconds (DCC-120) or Delayed Cord Clamping at 30 seconds (DCC-30) after birth lead to better health outcomes? * Does DCC-120 seconds or DCC-30 seconds after birth lead to better neuromotor outcomes at 22-26 months of infant age... Read More
Gender:
ALL
Ages:
Between 37 weeks and 42 weeks
Trial Updated:
01/17/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Congenital Heart Disease (CHD)
Register for Updates